Transforming science into medicine
We are committed to developing novel compounds in oncology that will deliver life-changing innovations for patients.
Pipeline
Motixafortide (BL-8040)
Stem Cell Mobilization
Motixafortide (BL-8040) blocks the interaction between CXCL12 and CXCR4 leading to robust mobilization of stem cells to the peripheral blood for collection and transplant.
Pipeline
Motixafortide (BL-8040)
Solid Tumors
Motixafortide (BL-8040) mobilizes immune cells to peripheral blood circulation, leading to Increase in immune cell infiltration into tumors and reduction in immunosuppression in tumor microenvironment.
Pipeline
AGI-134
Solid Tumors
AGI-134 is a universal drug that evokes a vaccine effect via a unique, hyper-acute, multi-arm mechanism that targets patient-specific neoantigens
Partnering
In-licensing
BioLineRx is committed to the identification, in-licensing and systematic development of promising therapeutic candidates. Through this strategy, BioLineRx is building a pipeline of powerful technologies in oncology.
Out-licensing
BioLineRx seeks to collaborate with leading global pharmaceutical companies with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative developments to market. We believe that this is the way to combine our drug development expertise with your commercial development capabilities.
Investors
Change 0.02 (1.23 %)
Volume 196,820
Exchange NASDAQ
1.62
38.70